By a News Reporter-Staff News Editor at Women's Health Weekly -- GTx, Inc. (Nasdaq: GTXI) announced a scientific presentation will be made at the 2013 San Antonio Breast Cancer Symposium, December 10-14, 2013, in San Antonio, Texas, involving technology licensed from the University of Tennessee Research Foundation and developed by the Company (see also GTx, Inc.).
The presentation will take place on December 13, 2013 in Exhibit Hall, A and B:Poster Session 5: Tumor Cell and Molecular Biology: Endocrine Therapy and ResistanceP5-09-21Selective Androgen Receptor Modulators (SARMs): Enobosarm as Targeted Therapy for the Treatment of Androgen Receptor-Positive Breast Cancer.Drs. James T. Dalton, Ramesh Narayanan and Mitchell S. Steiner of GTx, Inc. and Dr. Beth Overmoyer, Director, Inflammatory Breast Cancer Program, Dana Farber Cancer Institute and Assistant Professor of Medicine at the Harvard Medical School
"We are delighted to be able to showcase important preclinical data affirming our belief that enobosarm can become an important additional hormonal treatment option for women with advanced breast cancer," said Dr. Mitchell Steiner, CEO and Vice-Chairman of GTx, Inc. "Medical literature shows that 75 to 95% of women with estrogen positive breast cancer also express androgen receptor positive. Enobosarm has the potential to provide a nonsteroidal, tissue-selective novel targeted approach to exploit the therapeutic benefits of androgen therapy in breast cancer without the unwanted virilizing side effects or concerns associated with non-tissue selective androgens, such as facial and body hair, enlargement of the voice box, acne and edema."
GTx is currently conducting a proof of concept, Phase 2, open-label clinical study to evaluate enobosarm (GTx-024), a selective androgen receptor modulator (SARM), for the potential treatment of metastatic breast cancer. The company expects to complete enrollment of the approximately 20 patients for this study in December, 2013 and receive data from the study late in the second quarter of 2014. About Breast Cancer And Receptor Status Breast cancer is the most commonly diagnosed cancer in women, and the second leading cause of cancer deaths in women in the United States. Each year, over 200,000 new cases of invasive breast cancer will be diagnosed in the U.S., and approximately 39,000 women will die from the disease. Clinical assessment of breast cancer includes routine characterization of a patient's receptor status, including the presence or absence of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2) in the tumor tissue. Receptor status is used to assess the potential for developing metastatic disease, as well as guiding treatment decisions. Hormonal manipulation with selective estrogen receptor modulators or aromatase inhibitors is the standard treatment given to patients with tumors that are ER positive. It is expected that a majority (70-95%) of women with ER positive breast cancer will also express androgen receptor (AR) in their primary tumor samples. High percentages (72-84%) of metastatic breast cancer lesions have also been found to be AR positive. In preclinical and clinical studies, androgens have been shown to suppress breast cancer growth. In addition, prior studies have shown that women with metastatic breast cancer who have been previously treated with tamoxifen and progress have responded to nonselective androgens like fluoxymesterone, medroxyprogesterone and danazol, with overall response rates ranging from 20 to 60%. Although these nonselective androgens have been used to treat breast cancer, the unwanted virilizing side effects, including facial and body hair, enlargement of voice box, acne, and edema, have limited their widespread clinical use. About GTx GTx, Inc., headquartered in Memphis, Tenn., is a biopharmaceutical company dedicated to the discovery, development, and commercialization of small molecules for the treatment of cancer, cancer supportive care, including prevention and treatment of cancer-related muscle wasting, and other serious medical conditions.
Keywords for this news article include: Cancer, GTx Inc., Hormones, Oncology, Estrogens, Treatment, Therapeutics, Endocrinology, Women's Health, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC